Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2008

01.04.2008 | Epidemiology

Population screening and intensity of screening are associated with reduced breast cancer mortality: evidence of efficacy of mammography screening in Australia

verfasst von: D. Roder, N. Houssami, G. Farshid, G. Gill, C. Luke, P. Downey, K. Beckmann, P. Iosifidis, L. Grieve, L. Williamson

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2008

Einloggen, um Zugang zu erhalten

Abstract

Background

Efficacy of breast screening may differ in practice from the results of randomized trials. We report one of the largest case–control evaluations of a screening service.

Methods

Subjects included 491 breast-cancer deaths affecting 45–80-year-old South Australian females during 2002–2005 (diagnosed after BreastScreen commencement) and 1,473 live controls (three per death) randomly selected from the State Electoral Roll after birth-date matching. Cancer Registry and BreastScreen records provided cancer and screening details. Risk estimates were calculated by BreastScreen participation, using conditional logistic regression. Interpretation was assisted by a population survey of risk factor prevalence by BreastScreen participation in 1,684 females aged ≥40 years.

Results

The relative odds (OR) (95% confidence limits) of breast-cancer death in BreastScreen participants compared with non-participants were 0.59 (0.47, 0.74). Compared with non-participants, the OR was 0.70 (0.47, 1.05) for women last screened through BreastScreen more than 3 years before diagnosis of the index case, and 0.57 (0.44, 0.72) for women screened more recently. The OR of 0.47 (0.34, 0.65) for women screened more frequently in the pre-diagnosis phase was lower than the 0.64 (0.50, 0.82) for other screened women. The overall OR of 0.59 approximated 0.70 when corrected for the screening self-selection bias observed in five randomized trials. However, multivariable analysis of survey data did not indicate a lower prevalence of breast-cancer risk factors among BreastScreen participants, suggesting that this correction may be inappropriate.

Conclusions

Participation in screening was associated with a breast-cancer mortality reduction of between 30 and 41%, depending on assumptions about screening self-selection bias. A downward mortality risk by recency of last screen prior to cancer diagnosis, and frequency of recent screening, is consistent with a screening effect.
Literatur
1.
Zurück zum Zitat Demissie K, Mills OF, Rhoads GG (1998) Empirical comparison of the results of randomised controlled trials and case-control studies in evaluating the effectiveness of screening mammography. J Clin Epidemiol 51:81–91PubMedCrossRef Demissie K, Mills OF, Rhoads GG (1998) Empirical comparison of the results of randomised controlled trials and case-control studies in evaluating the effectiveness of screening mammography. J Clin Epidemiol 51:81–91PubMedCrossRef
2.
Zurück zum Zitat Shapiro S, Venet W, Strax P, Venet L, Roeser R (1985) Selection, follow-up and analysis in the health insurance plan study: a randomised trial with breast cancer screening. Natl Cancer Inst Monogr 67:65–74PubMed Shapiro S, Venet W, Strax P, Venet L, Roeser R (1985) Selection, follow-up and analysis in the health insurance plan study: a randomised trial with breast cancer screening. Natl Cancer Inst Monogr 67:65–74PubMed
3.
Zurück zum Zitat Andersson I, Aspegren K, Janzon L et al (1988) Mammographic screening and mortality from breast cancer: the Malmo mammographic screening trial. BMJ 297:943–948PubMedCrossRef Andersson I, Aspegren K, Janzon L et al (1988) Mammographic screening and mortality from breast cancer: the Malmo mammographic screening trial. BMJ 297:943–948PubMedCrossRef
4.
Zurück zum Zitat Tabar L, Fagerberg G, Duffy S, Day N, Gas A, Grontoft O (1998) Update of the Swedish two county program of mammographic screening trial. Radiol Clin North Am 51:81–91 Tabar L, Fagerberg G, Duffy S, Day N, Gas A, Grontoft O (1998) Update of the Swedish two county program of mammographic screening trial. Radiol Clin North Am 51:81–91
5.
Zurück zum Zitat Roberts MM, Alexander FE, Anderson TJ et al (1990) Edinburgh trial of screening for breast cancer: mortality at seven years. Lancet 335:241–246PubMedCrossRef Roberts MM, Alexander FE, Anderson TJ et al (1990) Edinburgh trial of screening for breast cancer: mortality at seven years. Lancet 335:241–246PubMedCrossRef
6.
Zurück zum Zitat Miller AB, Baines CJ, To T, Wall C (1992) Canadian national breast screening study, 1: breast cancer detection and death rates among women aged 40 to 49 years. Can Med Assoc J 147:1459–1476 Miller AB, Baines CJ, To T, Wall C (1992) Canadian national breast screening study, 1: breast cancer detection and death rates among women aged 40 to 49 years. Can Med Assoc J 147:1459–1476
7.
Zurück zum Zitat Miller AB, Baines CJ, To T, Wall C (1992) Canadian national breast screening study, 2: breast cancer detection and death rates among women aged 50 to 59 years. Can Med Assoc J 147:1477–1488 Miller AB, Baines CJ, To T, Wall C (1992) Canadian national breast screening study, 2: breast cancer detection and death rates among women aged 50 to 59 years. Can Med Assoc J 147:1477–1488
8.
Zurück zum Zitat Frisell J, Eklund G, Hellstrom L, Lidbrink E, Rutqvist LE, Somell A (1991) Randomized study of mammography screening: preliminary report on mortality in the Stockholm trial. Breast Cancer Res Treat 18:49–56PubMedCrossRef Frisell J, Eklund G, Hellstrom L, Lidbrink E, Rutqvist LE, Somell A (1991) Randomized study of mammography screening: preliminary report on mortality in the Stockholm trial. Breast Cancer Res Treat 18:49–56PubMedCrossRef
9.
Zurück zum Zitat Nystrom L, Rutqvist LE, Wall S et al (1993) Breast cancer screening with mammography: overview of Swedish randomised trials. Lancet 341:973–978PubMedCrossRef Nystrom L, Rutqvist LE, Wall S et al (1993) Breast cancer screening with mammography: overview of Swedish randomised trials. Lancet 341:973–978PubMedCrossRef
10.
Zurück zum Zitat World Health Organization (WHO), International Agency for Research on Cancer (IARC) (2002) IARC handbooks of cancer prevention, vol 7: breast cancer screening. IARC Press, Lyon World Health Organization (WHO), International Agency for Research on Cancer (IARC) (2002) IARC handbooks of cancer prevention, vol 7: breast cancer screening. IARC Press, Lyon
11.
Zurück zum Zitat Gabe R, Duffy SW (2005) Evaluation of service screening mammography in practice: the impact on breast cancer mortality. Ann Oncol 16(Suppl 2):ii153–ii162PubMedCrossRef Gabe R, Duffy SW (2005) Evaluation of service screening mammography in practice: the impact on breast cancer mortality. Ann Oncol 16(Suppl 2):ii153–ii162PubMedCrossRef
12.
Zurück zum Zitat Fielder HM, Warwick J, Brook D et al (2004) A case-control study to estimate the impact on breast cancer death of the breast screening programme in Wales. J Med Screen 11:194–198PubMedCrossRef Fielder HM, Warwick J, Brook D et al (2004) A case-control study to estimate the impact on breast cancer death of the breast screening programme in Wales. J Med Screen 11:194–198PubMedCrossRef
13.
Zurück zum Zitat South Australian Cancer Registry (1996) Epidemiology of cancer in South Australia. Incidence, mortality and survival, 1977 to 1995. Incidence and mortality, 1995. Openbook Publishers, Adelaide South Australian Cancer Registry (1996) Epidemiology of cancer in South Australia. Incidence, mortality and survival, 1977 to 1995. Incidence and mortality, 1995. Openbook Publishers, Adelaide
14.
Zurück zum Zitat Roder D (2006) Population screening—opportunities to strengthen cancer control. Public Health Bull S Aust 5:2–6 Roder D (2006) Population screening—opportunities to strengthen cancer control. Public Health Bull S Aust 5:2–6
15.
16.
Zurück zum Zitat Armitage P, Berry G (1987) Statistical methods in medical research, 2nd edn. Blackwell Scientific Publications, Oxford Armitage P, Berry G (1987) Statistical methods in medical research, 2nd edn. Blackwell Scientific Publications, Oxford
17.
Zurück zum Zitat StataCorp (2005) Stata statistical software. Release 9.2. StatCorp LP, College Station, TX StataCorp (2005) Stata statistical software. Release 9.2. StatCorp LP, College Station, TX
18.
Zurück zum Zitat Elmore JG, Reisch LM, Barton MB et al (2005) Efficacy of breast cancer screening in the community according to risk level. J Natl Cancer Inst 97:1035–1043PubMedCrossRef Elmore JG, Reisch LM, Barton MB et al (2005) Efficacy of breast cancer screening in the community according to risk level. J Natl Cancer Inst 97:1035–1043PubMedCrossRef
19.
Zurück zum Zitat Australian Bureau of Statistics (1998) 1996 census of population and housing. Socio-economic indexes for areas. Australian Bureau of Statistics, Canberra Australian Bureau of Statistics (1998) 1996 census of population and housing. Socio-economic indexes for areas. Australian Bureau of Statistics, Canberra
20.
Zurück zum Zitat Department of Health and Aged Care and the University of Adelaide (1999) Measuring remoteness: accessibility/remoteness index of Australia (ARIA). Occasional Papers: New Series No. 6. Commonwealth of Australia, Canberra Department of Health and Aged Care and the University of Adelaide (1999) Measuring remoteness: accessibility/remoteness index of Australia (ARIA). Occasional Papers: New Series No. 6. Commonwealth of Australia, Canberra
21.
Zurück zum Zitat Government of South Australia, Department of Health, Population Research and Outcomes Studies Unit (2006) Health Monitor, July and September, 2006. BreastScreen data report. Department of Health, Adelaide Government of South Australia, Department of Health, Population Research and Outcomes Studies Unit (2006) Health Monitor, July and September, 2006. BreastScreen data report. Department of Health, Adelaide
22.
Zurück zum Zitat Duffy SW, Hill C, Esteve J (eds) (2001) Quantitative methods for the evaluation of cancer screening. Oxford University Press, New York Duffy SW, Hill C, Esteve J (eds) (2001) Quantitative methods for the evaluation of cancer screening. Oxford University Press, New York
23.
Zurück zum Zitat Friedman DR, Dubin N (1991) Case-control evaluation of breast cancer screening. Am J Epidemiol 133:974–984PubMed Friedman DR, Dubin N (1991) Case-control evaluation of breast cancer screening. Am J Epidemiol 133:974–984PubMed
24.
Zurück zum Zitat Sasco AJ, Day NE, Walter SD (1986) Case-control studies for the evaluation of screening. J Chronic Dis 39:399–405PubMedCrossRef Sasco AJ, Day NE, Walter SD (1986) Case-control studies for the evaluation of screening. J Chronic Dis 39:399–405PubMedCrossRef
25.
Zurück zum Zitat Morrison AS (1982) Case definition in case-control studies of the efficacy of screening. Am J Epidemiol 115:6–8PubMed Morrison AS (1982) Case definition in case-control studies of the efficacy of screening. Am J Epidemiol 115:6–8PubMed
26.
Zurück zum Zitat Rhoads GG (1986) Use of case-control studies for evaluation of preventive health care. J Ambul Care Manage 9:53–64PubMed Rhoads GG (1986) Use of case-control studies for evaluation of preventive health care. J Ambul Care Manage 9:53–64PubMed
27.
Zurück zum Zitat Weiss NS (1983) Control definition in case-control studies of efficacy of screening and diagnostic testing. Am J Epidemiol 118:457–460PubMed Weiss NS (1983) Control definition in case-control studies of efficacy of screening and diagnostic testing. Am J Epidemiol 118:457–460PubMed
28.
Zurück zum Zitat Weiss NS (1994) Application of the case-control method in the evaluation of screening. Epidemiol Rev 16:102–108PubMed Weiss NS (1994) Application of the case-control method in the evaluation of screening. Epidemiol Rev 16:102–108PubMed
29.
Zurück zum Zitat Weiss N (1999) Case-control studies of the efficacy of screening tests to prevent the incidence of cancer. Am J Epidemiol 149:1–4PubMed Weiss N (1999) Case-control studies of the efficacy of screening tests to prevent the incidence of cancer. Am J Epidemiol 149:1–4PubMed
30.
Zurück zum Zitat Broeders MJ, Verbeek AL, Straatman H et al (2002) Repeated mammographic screening reduces breast cancer mortality along the continuum of age. J Med Screen 9:163–167PubMedCrossRef Broeders MJ, Verbeek AL, Straatman H et al (2002) Repeated mammographic screening reduces breast cancer mortality along the continuum of age. J Med Screen 9:163–167PubMedCrossRef
31.
Zurück zum Zitat Feig SA (1996) Methods to identify benefit from mammographic screening in women aged 40–49 years. Editorial. Radiology 201:309–316 Feig SA (1996) Methods to identify benefit from mammographic screening in women aged 40–49 years. Editorial. Radiology 201:309–316
32.
Zurück zum Zitat Duffy SW, Cuzick J, Tabar L et al (2002) Correcting for non-compliance bias in case-control studies to evaluate cancer screening programmes. Appl Stat 51:235–243 Duffy SW, Cuzick J, Tabar L et al (2002) Correcting for non-compliance bias in case-control studies to evaluate cancer screening programmes. Appl Stat 51:235–243
Metadaten
Titel
Population screening and intensity of screening are associated with reduced breast cancer mortality: evidence of efficacy of mammography screening in Australia
verfasst von
D. Roder
N. Houssami
G. Farshid
G. Gill
C. Luke
P. Downey
K. Beckmann
P. Iosifidis
L. Grieve
L. Williamson
Publikationsdatum
01.04.2008
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2008
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-007-9609-5

Weitere Artikel der Ausgabe 3/2008

Breast Cancer Research and Treatment 3/2008 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.